anal cancer

Incyte CEO Herv Hoppenot

Pharma

Incyte CEO views PD-1 drug Zynyz as oncology pipeline aide

Incyte plans to file Zynyz with the FDA soon for a new use, potentially making it the first PD-1 inhibitor approved for first-line anal cancer.

Angus Liu Sep 14, 2024 10:30am

question unanswered wonder ask

Incyte touts 2 trial wins for PD-1 drug Zynyz amid I-O retreat

Jul 30, 2024 11:27am

St. Jude's campaign educates about on-time HPV vaccine

Oct 13, 2022 8:50am